Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 63

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 63
---
 Provision related to:Current year sales4,645 104,957 16,680 126,282 Prior year sales(6,988)253 99 (6,636)Total provision(2,343)105,210 16,779 119,646 Less: Actual payments/credits(1,107)(100,332)(15,362)(116,801)Balance at March 31, 2025$49,925 $120,208 $13,764 $183,897 

Accrued Product Returns and RebatesProductReturnsProductRebatesSales DiscountsTotalBalance at December 31, 2023$57,290 $96,984 $10,719 $164,993 Provision related to:Current year sales5,640 100,301 15,812 121,753 Prior year sales(1,403)668 38 (697)Total provision4,237 100,969 15,850 121,056 Less: Actual payments/credits(1,982)(90,272)(14,531)(106,785)Balance at March 31, 2024$59,545 $107,681 $12,038 $179,264 

Accrued Product Returns and Rebates

The accrued product returns balance decreased to $49.9 million as of March 31, 2025 from $59.5 million as of March 31, 2024. This decrease was primarily due to the $7.0 million of estimated provision for product returns related to prior year sales. The majority of the provision for product returns related to prior year sales is attributable to Qelbree, reflecting favorable actual returns experienced in 2025 for Qelbree. As a result, the Company changed its estimated provision for product returns based on the most recent experience.

The accrued product rebates balance increased to $120.2 million as of March 31, 2025 from $107.7 million as of March 31, 2024 primarily due to timing of payments associated with government programs. 

Provision for Product Returns and Rebates

The provision for product returns decreased to $(2.3) million for the three months ended March 31, 2025 from $4.2 million for the three months ended March 31, 2024. The decrease was primarily due to the aforementioned $7.0